Panbela Therapeutics, Inc.【PBLA】

Market cap

$63.36K

P/E ratio

	Dec 31, 2012	Dec 31, 2013	Dec 31, 2014	Dec 31, 2015	Dec 31, 2016	Dec 31, 2017	Dec 31, 2018	Dec 31, 2019	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023
Cash and cash equivalents	110,938	58,822	163,772	925,000	438,000	152,000	1	2	9	12	1	3
Prepaid expenses and other current assets	-	-	-	-	-	-	-	-	-	-	-	0
Income tax receivable	-	-	-	733,000	321,000	420,000	332,000	361,000	323,000	0	0	183,000
Total current assets	336,809	432,843	391,077	2	1	1	2	3	10	12	2	3
Other noncurrent assets	-	-	-	0	-	-	0	0	0	1	3	9
Total assets	610,906	532,261	407,116	2	1	1	2	3	10	13	5	12
Accounts payable	28,142	3,995	340	1	1	1	1	1	1	1	3	10
Accrued expenses	10,262	51,420	22,043	1	1	1	0	0	1	2	3	1
Accrued interest payable	-	-	-	0	0	0	0	-	-	-	0	0
Note payable	-	-	-	-	-	-	-	-	-	-	1	-
Debt, current portion	-	-	-	-	-	-	-	-	-	-	1	1
Total current liabilities	643,504	663,695	615,662	1	6	4	2	2	1	3	8	12
Debt, net of current portion	-	-	-	0	-	0	-	-	-	-	5	4
Total non current liabilities	8,249	6,458	2,413	3	-	0	-	-	-	-	5	4
Total liabilities	651,753	670,153	618,075	-	-	-	-	2	1	3	13	17
Preferred stock, $0.001 par value; 10,000,000 authorized; no shares issued or outstanding as of December 31, 2022 and December 31, 2021	200,119	200,119	200,119	-	-	-	-	-	-	-	-	-
Common stock, $0.001 par value; 100,000,000 authorized; 1,049,644 and 335,961 shares issued and outstanding, as of December 31, 2022 and December 31, 2021, respectively	86,033	86,033	86,033	0	0	0	0	0	0	0	0	-
Treasury Stock at cost; 70 and 0 shares as of December 31, 2023 and December 31, 2022, respectively	-	-	-	-	-	-	-	-	-	-	-	0
Additional paid-in capital	13	13	13	11	14	26	35	42	55	66	82	120
Accumulated deficit	-13,669,971	-13,881,992	-13,989,036	-14	-19	-29	-35	-41	-46	-56	-91	-125
Accumulated comprehensive income	-	-	-	0	0	-0	0	0	-0	0	1	1
Total stockholders' (deficit) equity	-40,847	-137,892	-210,959	-3	-5	-4	0	1	8	10	-8	-5
Total liabilities and stockholders' (deficit) equity	610,906	532,261	407,116	2	1	1	2	3	10	13	5	12